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ABSTRACT

Introduction: The use of dasatinib in patients with CML has improved life expectancy and follow-up with transthoracic
echocardiography (ECOTT) for early detection of PAH allows modifications to the treatment. Objectives: To determine the
echocardiographic parameters and echocardiographic probability for PAH in patients with CML treated with dasatinib.
Methods: Correlation, cross-sectional, retrospective, single-center study; patients with CML treated with dasatinib were
included. Spearman and Pearson correlation was used. Results: 16 patients were analyzed, mean age 53.5 years; 62.5%
men, 37.5% women. The dasatinib dose was 50 mg / day in 18.7%, and 100 mg / day in 81.2%, mean pulmonary arterial
pressure (mPAP) 26.3 mmHg, mean maximum tricuspid regurgitation velocity (VmxRT) 2.9 m / s, mean pulmonary artery
systolic pressure (PSAP) 41 mmHg. 56.2% had right ventricular diastolic dysfunction (RVDD). 43% were categorized as
low probability for PAH, 18.7% intermediate, and 37.5% as high. Relationship between PAPm and VmxRT with p = 0.012.
Relationship between mPAP and RV diastolic function, with p = 0.002. Relationship between probability for PAH and mPAP,
with p = 0.008. Conclusions: The echocardiographic parameters PAPm, VmxRT, PSAP, DDVD and echocardiographic
probability for PAH are useful and necessary for the diagnosis of PAH. The determination of all these parameters should be
carried out early and as a follow-up, since a considerable positive relationship was found for each one with the presence of
PAH, which is not dependent on the treatment time or the dose of dasatinib.
Key words: Pulmonary arterial hypertension; Leukemia; Dasatinib; Echocardiogram (source: MeSH NLM).

RESUMEN

Introducción: La leucemia mieloide crónica (LMC) es un desorden clonal de células madre hematopoyéticas, predomina
en el género masculino entre 55 y 65 años. El ecocardiograma transtorácico (ECOTT) para detección temprana de
hipertensión arterial pulmonar (HAP) permite hacer modificaciones al tratamiento con dasatinib. Ojetivos: Determinar
los parámetros ecocardiográficos y la probabilidad ecocardiográfica para HAP en pacientes con LMC tratados con
dasatinib. Métodos: Estudio de correlación, transversal, retrospectivo, unicéntrico; se incluyeron pacientes con LMC
tratados con dasatinib. Se utilizó correlación de Spearman y Pearson. Resultados: Se analizaron 16 pacientes, edad
promedio 53,5 años; 62,5% hombres, 37,5% mujeres. La dosis de dasatinib fue 50 mg/día en 18,7%, y 100 mg/día en
81,2%, presión media de la arteria pulmonar (mPAP) 26,3 mmHg, velocidad máxima de regurgitación tricuspídea (VmxRT)
media 2,9 m/s, presión sistólica de arteria pulmonar (PSAP) media 41 mmHg. El 56,2% presentó disfunción diastólica
del ventrículo derecho (DDVD). Se categorizaron 43% en baja probabilidad para HAP, 18,7% intermedia y 37,5% en alta.
Relación entre mPAP y VmxRT con p=0,012. Relación entre mPAP y función diastólica del ventrículo derecho (FDVD), con
p=0,002. Relación entre probabilidad para HAP y mPAP, con p=0,008. Conclusión: Los parámetros ecocardiográficos
mPAP, VmxRT, PSAP, DDVD son útilesy la probabilidad ecocardiográfica para HAP deben realizarse de forma temprana y
como seguimiento, ya que se encontró relación positiva con la presencia de HAP, la cual no es dependiente del tiempo de
tratamiento ni de la dosis de dasatinib.
Palabras clave: Hipertensión arterial pulmonar; Leucemia; Dasatinib; Ecocardiograma (fuente: DeCS BIREME).
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INTRODUCTION

Pulmonary Hypertension (PH) results from flow
restriction in pulmonary artery circulation,
culminating in right heart failure. It is characterized
by a mPAP ≥25 mmHg at rest (normal at rest 14 ± 3).
Patients presenting in the mPAP range between 2124 mmHg should be followed when they are at risk
of developing PAH(12,13). TKI-induced PAH has a low
incidence and the dose of dasatinib does not appear
to be correlated with the risk of developing PAH(14).
Regarding the mechanism of PAH, induced by
dasatinib, it is known that it inhibits the Src family
of kinases that participate in cell proliferation and
regulate AP smooth muscle tone through the
potassium channel-1 pathway sensitive to TWIK2. It leads to depolarization of smooth muscle
cells, vasoconstriction, and increased pulmonary
arterial pressure; at the same time, it has an indirect
association with the production of nitric oxide and
prostaglandins responsible for vascular relaxation,
so that by inhibiting the Scr signaling pathways an
imbalance between dilation and vasoconstriction
occurs(15,16).
https://inicib.urp.edu.pe/rfmh/vol21/iss4/3
DOI: https://doi.org/10.25176/RFMH.v21i4.4265

Echocardiographic diagnosis of PAH is probably
when VRT> 3.4 m / s. It is possible when the VTR is
between 2.9-3.4 m / s or when TRV ≤ 2.8 m / s with
additional variables that suggest PAH (dilation
of the right chambers, hypertrophy of the right
ventricle, dilation of the pulmonary artery trunk)
(21,22)
. By color Doppler echocardiography, mean
pulmonary artery pressure (mPA) can be estimated
using acceleration time in the ventricular outflow
tract(23). The use of tissue Doppler to measure (FDVD)
is considered useful and characteristic in PAH. In
2005, they describe a significant increase in the
isovolumic relaxation time (IVRT); currently there is
validation of the correlation of IVT with PAH, PSAP
and diastolic dysfunction(24). In 2017, Skride et al.(25),
presented a case report, a 67-year-old man with
CML treated with dasatinib. After treatment, she
presented pleural effusion; Severe PAH with 53
mmHg mPAP was confirmed by ECOTT and by right
heart catheterization. Given these findings, dasatinib
was discontinued. A one-month follow-up study
showed a significant improvement in mPAP of 34
mmHg. In 2016, Morishita et al.(26), presented a report
of a patient with CML who had been administered
dasatinib for three years; 34 months later, the patient
presented exertional dyspnea, there was no increase
in pleural effusion (which she had previously
presented); PAH was suspected by ECOTT. PAH was
then confirmed by cardiac catheterization.
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Chronic myeloid leukemia (CML) is a clonal
hematopoietic stem cell disorder; is characterized
by the presence of Philadelphia chromosome (Ph)
with reciprocal translation between chromosomes
9 and 22, resulting in BCR-ABL, which encodes
a constitutively active tyrosine kinase (TK)(1,2). It
predominates in male sex (ratio 1.6: 1). The mean age
at diagnosis is between 55-65 years old. Diagnosis
depends on finding the abnormal Philadelphia
chromosome t (9;22) (q34;q11.2)(3).The clinical use
of tyrosine kinase inhibitors(TKI) was selectively
directed at blocking the enzymatic activity of BCRABL, imatinib being the first available drug.(4). The
need to improve existing therapies gave rise to
a second generation of ITK, with drugs such as
dasatinib. Dasatinib is 325 times more potent than
imatinib. The FDA approved the use of this drug for
the treatment of CML in Philadelphia chromosome
positive patients(5,6). Dasatinib inhibits multiple TKs,
including BCR-ABL1, platelet-derived growth factor
receptor β, and Src family kinases(7,8). The adverse
reactions of dasatinib were discovered during clinical
studies leading to its approval. From the phase 1
clinical trial, grade 3 and 4 toxicities were observed.
In the phase III DASISION clinical trial (2016), pleural
effusion (associated with elevated pulmonary
arterial pressures) was reported in 28% of cases and
14 ( 5%) patients presented PAH(9-11).

In the diagnosis of PAH by echocardiography, right
heart catheterization is the technique of choice, being
an invasive procedure with multiple complications.
Because the symptoms of PAH are nonspecific and
the physical signs are subtle, the diagnosis is usually
late and in advanced stages of the disease, for this
reason it is necessary to have non-invasive and lowrisk techniques that have a high rate of efficacy to
detect PAH before irreversible physiological damage
occurs. By transthoracic echocardiography (ECOTT),
direct and indirect signs of elevated pulmonary
arterial pressure (PAP) can be obtained, which is
useful for the diagnosis and prognosis of PAH(19,20).
The tricuspid regurgitation velocity (TRV) parameters
used to estimate pulmonary artery systolic pressure
(PASP) since there is a good correlation with PAP
measured by right heart catheterization.

In 2016, Minami et al.(27) presented a comparative
analysis of PAH in patients treated with different TK
inhibitors; ECOTT was used to assess the incidence
of PAH in 105 CML patients treated with imatinib (n
= 37), nilotinib (n = 30) or dasatinib (n = 38), using
the mean peak tricuspid regurgitation gradient
Pág. 683
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(TRPG). A TRPG> 31 mmHg suggested possible
PAH in nine of 105 patients: one (2.7%) treated
with imatinib, three (10.0%) with nilotinib, and five
(13.2%) with dasatinib. These results suggested that
treatment with dasatinib, imatinib and nilotinib may
be associated with subclinical PAH, concluding that
non-invasive echocardiography is useful for the
detection of PAH in patients treated with second
generation TKI.
In 2016 Jin et al.(28) presented the case of a 55-yearold man with CML treated with dasatinib at a dose
of 100 mg per day. After 36 months of treatment, he
presented with dyspnea, fatigue and edema. ECOTT
was performed in which growth of the right ventricle
and atrium was documented, with PSAP estimated
at 115 mmHg and pericardial effusion. He presented
improvement when stopping dasatinib treatment,
documenting a reduction in PSAP 37-82 mmHg
measured on three occasions. In 2016 Nagasaki et
al.(29) reported the case of a 59-year-old man, with
CML treated for five years, at a dose of 100 mg per
day. He presented dyspnea with deterioration of
functional class. ECOTT was performed finding PAH
data, with PSAP of 80 mmHg and a PAPm of 29 mmHg.
Treatment was discontinued, showing a decrease in
PSAP of 51 and 40 mmHg at the first month and year
respectively. In 2015 Hong et al.(30), reported two
cases of CML patients treated with dasatinib. One
case was a 43-year-old man, who after 69 months
of treatment presented with dyspnea, performing
ECOTT with PSAP of 92 mmHg, enlargement of the
right ventricle and atrium, as well as mild pleural
effusion. The second case was a 52-year-old man,
who presented dyspnea, ECOTT was performed with
PSAP 71 mmHg, mild pleural effusion. Both cases
presented improvement and decrease in PSAP after
discontinuation of dasatinib.
The use of dasatinib in patients with CML has
improved life expectancy; however, drug toxicity
(PAH) has been documented and may become
irreversible. In the early stages of PAH, most patients
can be asymptomatic and can be detected by ECOTT.
Performing an echocardiogram is inexpensive and
takes a relatively short time. It focuses on measuring
PSAP and PAH-related findings. Furthermore, it is
important to measure FDVD, since the right heart
chambers are affected in the long term. The followup of patients treated with dasatinib, by means of
ECOTT is important for the early detection of PAH and
to be able to make modifications to the treatment.
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Therefore, the objective of this study was to
determine the useful echocardiographic parameters
to diagnose PAH in patients with CML under
treatment with dasatinib, in order to make an early
diagnosis and follow-up.

METHODS
An observational, cross-sectional, retrospective,
retrolective,
single-center
and
homodemic
correlation study was carried out. The design and
type of sampling was deterministic. Patients from
the Hematology Service with a diagnosis of CML
under treatment with dasatinib were studied.
Patients older than 18 years and younger than
80 years were included. Patients with incomplete
echocardiographic data were excluded. A total
population of 31 patients was obtained, of which
15 were excluded because they did not have an
echocardiographic study in the work base.
The study data were obtained from the clinical record
and from the syngo SC2000 workplace database
located in the cardiology office. The right ventricular
diastolic function was measured by ECOTT, mPAP,
VmxRT, PSAP, and the echocardiographic probability
for pulmonary hypertension was determined; The
dasatinib dose indicated in each patient was identified,
as well as the treatment time. An Excel database was
prepared and it was established whether or not there
is PAH and what echocardiographic findings are
related. PAH was considered from mPAP greater than
25 mmHg. Echocardiographic parameters related to
PAH were considered as VmxRT greater than or equal
to 2.8 m / s, PSAP greater than 35 mmHg and DDVD.
The data were analyzed with descriptive statistics,
using measures of central tendency and dispersion,
using parametric and non-parametric statistical tests
(Spearman and Pearson correlation). The analysis
was performed using Excel version 16.39 and SPSS
version 26. Human, material and financial resources
were provided by the main investigators of the study.
The study was approved by the Comité Local de
Investigación en Salud. This study was designed in
accordance with the Reglamento de la ley General
de Salud (reglamento de la Ley General de Salud en
materia de investigación para la salud). It adhered to
the ethical standards drawn up in Helsinki in 1972
and modified in 1989. It was submitted for evaluation
by the local research committee of our Medical Unit.
The privacy of the patients studied was protected.
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RESULTADOS

patients (56.2%) were found with DDVD and seven
patients (43.7%) with normal FDVD. In respect of
probability for PAH, seven patients (43%) were
categorized as low probability, three patients (18.7%)
for intermediate probability, and six patients (37.5%)
for high probability. Of the patients with a history of
DM2, HAC and CKD, two patients (100%) were found
with PAH and DDVD, as well as Vmx RT> 2.8 m / s
and PSAP> 35 mmHg. The patient with isolated CKD
was found with DDVD, Vmx RT> 2.8 m / s and PSAP>
35 mmHg (classified as high echocardiographic
probability for PAH). No report similar to those
obtained was found in previous studies.
The relationship between the treatment time with
dasatinib and the mPAP figures had a value of r =
-0.315 with a value of p = 0.235. The relationship
between mPAP and dasatinib dose had a value of r
= 0.122 with a value of p = 0.653. The relationship of
mPAP with PSAP had a value of r = 0.647 and a value
of p = 0.007 (Graph 1). The relationship between
mPAP and VmxRT had a value of r = 0.612 and a value
of p = 0.012 (Graph 2). The relationship between
mPAP and FDVD had a value of r = 0.708 and a value
of p = 0.002 (Graph 3). The relationship between the
probability for PAH with mPAP had a value of r =
0.706 and a value of p = 0.008 (Graph 4).

ORIGINAL PAPER

A total of 16 patients were analyzed (Table 1 and 2
for statistical analysis), the mean age was 53.5 years,
with a SD of 11.7. Regarding gender, 10 patients were
male (62.5%) and six female (37.5%). Of the total
number of patients, two (12.5%) had concomitant
diagnoses of type 2 diabetes mellitus (DM2), chronic
arterial hypertension (HAC) and chronic kidney
disease (CKD); one patient (6.2%) had isolated stage
3a CKD, no ischemic heart disease or structural
heart disease was found; 13 patients (81.3%) did
not present comorbidities. This is different from the
study published by Minami et al.(27) in 2017, who
among the comorbidities reported a patient with
chronic ischemic heart disease, without reporting
other comorbidities. These results in the patients
studied were due to the prevalence in our setting of
DM2 and hypertension and the presence of CKD as
a complication associated with such comorbidities.
Regarding the dose of dasatinib, three patients
were administered 50 mg per day (18.7%), and in 13
patients 100 mg per day (81.2%). As for mPAP, it had
a mean of 26.3 mmHg, SD 13.63. With the variable
VmxRT, a mean of 2.9 m / s, SD 0.51, was obtained.
Regarding PSAP, a mean of 41 mmHg, SD 14.02,
was obtained. Of the total number of patients, nine

Table 1. Statistical analysis of quantitative variables.
Variables

Mean

Minimum

Maximum

Standar deviation

Tiempo

146,2

14,7

381,4

101,26

PSAP

41

18

70

14,02

Vmx RT

2,9

2,1

4.0

0,51

mPAP

26,3

2,5

49,1

13,63

PASP: pulmonary artery systolic pressure, VmxTR: maximum velocity of tricuspid regurgitation, mPAP: mean pulmonary artery pressure

https://inicib.urp.edu.pe/rfmh/vol21/iss4/3
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Table 2. Statistical analysis of quantitative variables: dasatinid dose, FDVD and probability for PAH.
Dosis de
dasatinib

No. patients

Percentaje

Reason

Rate

Sampling
error

95% confidence
interval

50 mg

3

18,8%

0,23

23

9,75

0,41<18,75<37,86

100 mg

13

81,3%

4,33

433

9,75

62,14<81,25<100

Total

16

DFRV

No. patients

Percentaje

Reason

Rate

Sampling
error

95% confidence
interval

Normal

7

43,7%

1

100

12,4

19,3<43,7<68

Dysfunction

9

56,3%

1,29

129

12,4

32<56,3<80,6

Total

16

Dosis de
dasatinib

No. patients

Percentaje

Reason

Rate

Sampling
error

95% confidence
interval

Probability
for PAH

No. patients

Percentaje

Reason

Rate

Sampling
error

95% confidence
interval

low

7

43,7%

2,3 1,16

230

116

12,4

19,4<43,7<68

Intermediate

3

18,8%

0,42 0,5

42

50

9,76

0,32<18,8<37,9

High

6

37,5%

0,85 2

85

200

12,1

13,8<37,5<61,2

Total

16

DFRV: diastolic function of the right ventricle, PAH: pulmonary arterial hypertension.

Graphic 1. Correlation scatter diagram between mPAP (x) and PSAP (y).
mPAP: mean pulmonary artery pressure.
PASP: pulmonary artery systolic pressure.
r=0,647, p=0,007
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Graphic 2. Scatter diagram of correlation between mPAP (x) and VmxRT (y).
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mPAP: mean pulmonary artery pressure.
VmxRT: maximum speed of tricuspid regurgitation.
r= 0,612, p=0,012

Graphic 3. Scatter diagram of correlation between mPAP (x) and FDVD (y).
mPAP: mean pulmonary artery pressure.
FDVD: right ventricle.
r= 0,708, p=0,002

Graphic 4. Scatter diagram of correlation between mPAP (x) and probability for HAP (y).
mPAP: mean pulmonary artery pressure.
PAH: pulmonary arterial hypertension.
r=0,706, p=0,008
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DISCUSSION
CML is a hematopoietic clonal disorder that can
progress to an accelerated phase and death. The
use of dasatinib has shown a good hematological
and cytogenic response, however it is associated
with PAH, which is the result of excessive abnormal
proliferation of smooth muscle. The development
of PAH conditions involvement of the right heart
chambers (diastolic dysfunction), which confers a
worse prognosis. Echocardiographic measurements
to evaluate the presence of PAH are varied, being the
mPAP obtained by acceleration time of RVOT one of
the most reliable. Other echocardiographic values,
when mPAP is not available or is not considered
reliable, suggest a probability of PAH, classifying the
probability as high, intermediate, or low. In addition,
through the use of pulsed and tissue Doppler, it is
possible to obtain the FDVD, which is not dependent
on the measurement obtained from mPAP.
Of the total of patients studied with CML treated with
dasatinib, nine (56.2%) present echocardiographic
changes related to PAH, of which seven patients have
an estimated mPAP> 25 mmHg and two patients
have an intermediate and high probability for PAH
(with mPAP < 25 mmHg).
As additional findings, five patients had mild
pericardial effusion and one also presented pleural
effusion, four presented mPAP greater than 25
mmHg and the one with mPAP less than 25 mmHg
presented intermediate probability for PAH. All five
had DDVD, a PSAP> 35 mmHg and VmxRT> 2.8 m
/ s. Two patients in the sample without pericardial
effusion presented isolated pleural effusion. No
previous record was found of the study of pericardial
or pleural effusion in patients with CML treated with
dasatinib.
Other echocardiographic findings were the presence
of mild valvular disease: three patients with only
tricuspid regurgitation (TR); four patients with only
mitral regurgitation (MR), of which one did not
present PAH data; two patients with MI and mild TI,
of which one did not present PAH data. Regarding
these valvular heart diseases, the algorithm was
used to determine the filling pressures of the left
ventricle (LV) and diastolic dysfunction, obtaining
from patients with only TI and PAH two patients
with grade I diastolic dysfunction with normal left
atrial (LA) pressure and an indeterminate patient;
of the patients with MI only, one patient with grade
II diastolic dysfunction with increased LA pressure
and two patients with grade I diastolic dysfunction,
Pág.
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with normal LA pressure; the patient with MI and TI
together with PAH was classified as indeterminate.
There are no previous studies of valvular heart
disease in CML patients treated with dasatinib.
These results are considered comorbidities, since
two patients were not found with PAH, only in one
was an increase in filling pressures that influence
the presence of PAH due to the presence of grade II
diastolic dysfunction and not due to the presence of
mild MI. , four patients had normal filling pressures,
and two were indeterminate. At the end of the study,
the death of three patients included in the sample
was reported. One patient died due to progression
of the disease to the blast phase, and two patients
due to complications associated with pre-existing
comorbidities (DM2 and CKD). The three patients
complied with mPAP ≥ 25 (PAH), presented DDVD,
PSAP> 35 mmHg, VmxRT> 2.8 m / s, and high
probability for PAH. No previous studies were found
on mortality from PAH in CML patients treated
with dasatinib. The results of the study are due to
the presence of comorbidities that influence the
progression of PAH. The relationship between the
dasatinib treatment time and the mPAP figures of
the studied patients was found using the Spearman
equation; a value of R = -0.315 (mean negative
correlation) was obtained, resulting in a nonsignificant p.
In the study carried out by Minami et al.(27), in 2017,
a weak negative relationship was found with a
non-significant p. In the study carried out, there is
a relationship between the dose and the presence
of PAH, but no statistical significance was found,
that is, the increase in the dose is not necessarily
accompanied by an increase in mPAP. Regarding the
relationship of mPAP with PSAP, a value of r = 0.647
(considerable positive correlation) was obtained
with a significant p value (0.07), that is, the increase
in mPAP is accompanied by an increase in PSAP; no
previous studies of the relationship between mPAP
and PSAP were found. The relationship between
mPAP and VmxRT was evaluated, finding a value of r
= 0.612 (considerable positive correlation), a value of
p = 0.012 was obtained, being statistically significant,
that is, the increase in mPAP is accompanied by
an increase in VmxRT; no previous studies were
found evaluating the relationship between mPAP
and VmxRT. The relationship between mPAP and
FDVD was evaluated, obtaining a value of r =
0.708 (considerable positive correlation), with a
significant p value (0.02). No antecedents were
found in previous studies that have correlated mPAP
7
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positive correlation with PAH estimated by mPAP,
specifically when PAH cannot be ruled out only
with an echocardiographic parameter and it is
not feasible to perform an invasive study by right
catheterization. The aim is to introduce the routine
evaluation of FDVD in patients treated with TKI since
this finding appears early and translates into disease
progression. Also, to enter the field of cardioncology
to carry out early cardiovascular diagnoses (by
ECOTT), and to establish treatments aimed at heart
failure and PAH in cancer patients who should be
treated with some TKI.

With the evaluation of the relationship between
echocardiographic findings, a significant association
was found between the estimation of mPAP (to define
PAH by echocardiography when mPAP≥25 mmHg)
and the echocardiographic findings related to PAH
(VmxRT, PSAP), which are obtained independently
of mPAP; Furthermore, FDVD was evaluated, a
parameter that is not usually evaluated routinely
and that in this study was positively correlated with
mPAP and the presence of PAH. In addition, the
estimate of mPAP was significantly related to the
probability of PAH obtained by echocardiographic
findings. No previous studies were found where
a relationship of echocardiographic variables for
PAH in CML patients treated with dasatinib was
performed. These study results are due to the fact
that all echocardiographic findings are significantly
related to the presence of PAH (determined by
mPAP), where an echocardiographic estimate of
mPAP less than 25 mmHg does not exclude the
presence of PAH, and other evaluations must be
performed. echocardiographic.

Documenting PAH early in CML patients on dasatinib
is important for making changes in treatment or
taking action to limit cardiopulmonary damage.

This study aims to support the Cardiology and
Hematology Service, so that patients with CML
treated with dasatinib undergo close monitoring
with an echocardiogram prior to and during the start
of treatment, evaluating all the echocardiographic
parameters that showed usefulness, due to a

https://inicib.urp.edu.pe/rfmh/vol21/iss4/3
DOI: https://doi.org/10.25176/RFMH.v21i4.4265

The limitations of this research were the sample
size, which was affected by being a retrospective
study; Furthermore, since it is a correlational study,
the results found do not indicate the existence of a
cause-and-effect relationship between the variables
involved.
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with DDVD. In the study, the results are due to the
existence of DDVD in the patients with CML and PAH
studied. The relationship between the probability
for PAH with mPAP was evaluated, obtaining a value
of r = 0.706 (considerable positive correlation), the
p value obtained was significant (0.08); no study of
this relationship was found in previous publications.
This study result was obtained because there is a
significant relationship between the probability of
PAH and the mPAP value in the patients studied,
where the higher the mPAP value the greater the
probability of PAH.

CONCLUSION
The relation between dasatinib treatment time and
mPAP values had a medium negative correlation.
The relation of mPAP with the dose of dasatinib had
a mean positive correlation. Each of the following
relationships mPAP with PSAP, mPAP with VmxRT,
mPAP with FDVD, and probability for HAP with mPAP
had a considerable positive correlation.
The echocardiographic parameters mPAP, VmxRT,
PSAP, DDVD, and echocardiographic probability for
PAH are useful and necessary values to assess PAH.
The determination of all these parameters should
be carried out early and as a follow-up, since a
considerable positive relationship was found for
each one with the presence of PAH, which is not
dependent on the treatment time or the dose of
dasatinib.
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